Cargando…
Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform
SIMPLE SUMMARY: Patients with pancreatic cancer and other advanced cancers suffer from progressive weight loss that reduces treatment response and quality of life and increases treatment toxicity and mortality. Effective interventions to prevent such weight loss, known as cachexia, require molecular...
Autores principales: | Narasimhan, Ashok, Shahda, Safi, Kays, Joshua K., Perkins, Susan M., Cheng, Lijun, Schloss, Katheryn N. H., Schloss, Daniel E. I., Koniaris, Leonidas G., Zimmers, Teresa A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765482/ https://www.ncbi.nlm.nih.gov/pubmed/33334063 http://dx.doi.org/10.3390/cancers12123787 |
Ejemplares similares
-
Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways
por: Narasimhan, Ashok, et al.
Publicado: (2021) -
Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin
por: Zhong, Xiaoling, et al.
Publicado: (2022) -
Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
por: Kays, Joshua K., et al.
Publicado: (2018) -
The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy
por: Zhong, Xiaoling, et al.
Publicado: (2019) -
The impact of inflammation and acute phase activation in cancer cachexia
por: Robinson, Tyler P., et al.
Publicado: (2023)